Will India’s Sun Rise On Stada? Bankers, Analysts Divided On Risks, Benefits
This article was originally published in PharmAsia News
Executive Summary
Stada’s financial woes may not be primary factors for Sun to bid but analysts reason there may be value accretive points.
You may also be interested in...
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization
Germany's Discount Contracts Are Changing The Pharma Market Landscape
Regional firm wins an important tender, but at a discount that is so steep it attacks the process as creating "only losers."
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports